keyword
https://read.qxmd.com/read/38432220/practical-approaches-to-the-management-of-cardiorenal-disease-beyond-congestion
#21
REVIEW
Zorba Blazquez-Bermejo, Borja Quiroga, Jesús Casado, Rafael de la Espriella, Joan Carles Trullàs, Gregorio Romero-González, Jorge Rubio-Gracia, Javier Díez, Julio Núñez, Patricia de Sequera, Alejandro Recio-Mayoral, José Pérez-Silvestre, Marta Cobo Marcos
The coexistence of heart and kidney diseases, also called cardiorenal syndrome, is increasingly common, leads to a significant impact on morbidity and mortality, and poses diagnostic and therapeutic difficulties. There is a risk-treatment paradox, such that patients with the highest risk are treated with lesser disease-modifying medical therapies. In this document, different scientific societies propose a practical approach to systematically address and optimize cardiorenal therapies and related comorbidities in chronic cardiorenal disease beyond congestion...
March 2, 2024: Cardiorenal Medicine
https://read.qxmd.com/read/38427026/renal-congestion-in-heart-failure-insights-in-novel-diagnostic-modalities
#22
JOURNAL ARTICLE
Kyriakos Dimitriadis, Aikaterini Damianaki, Evanthia Bletsa, Nikolaos Pyrpyris, Panagiotis Tsioufis, Panagiotis Theofilis, Eirini Beneki, Fotis Tatakis, Alexandros Kasiakogias, Evangelos Oikonomou, Dimitrios Petras, Gerasimos Siasos, Konstantina Aggeli, Konstantinos Tsioufis
Heart failure is increasingly prevalent and is estimated to increase its burden in the following years. A well-reported comorbidity of heart failure is renal dysfunction, where predominantly changes in the patient's volume status, tubular necrosis or other mechanical and neurohormonal mechanisms seem to drive this impairment. Currently, there are established biomarkers evaluating the patient's clinical status solely regarding the cardiovascular or renal system. However, as the coexistence of heart and renal failure is common and related to increased mortality and hospitalization for heart failure, it is of major importance to establish novel diagnostic techniques, which could identify patients with or at risk for cardiorenal syndrome and assist in selecting the appropriate management for these patients...
February 29, 2024: Cardiology in Review
https://read.qxmd.com/read/38422175/cardiovascular-consequences-of-uremic-metabolites-an-overview-of-the-involved-signaling-pathways
#23
REVIEW
Adelina Curaj, Raymond Vanholder, Joseph Loscalzo, Kaiseng Quach, Zhuojun Wu, Vera Jankowski, Joachim Jankowski
The crosstalk of the heart with distant organs such as the lung, liver, gut, and kidney has been intensively approached lately. The kidney is involved in (1) the production of systemic relevant products, such as renin, as part of the most essential vasoregulatory system of the human body, and (2) in the clearance of metabolites with systemic and organ effects. Metabolic residue accumulation during kidney dysfunction is known to determine cardiovascular pathologies such as endothelial activation/dysfunction, atherosclerosis, cardiomyocyte apoptosis, cardiac fibrosis, and vascular and valvular calcification, leading to hypertension, arrhythmias, myocardial infarction, and cardiomyopathies...
March 2024: Circulation Research
https://read.qxmd.com/read/38420624/revolutionizing-biomedical-research-the-imperative-need-for-heart-kidney-connected-organoids
#24
JOURNAL ARTICLE
Sun-Sook Song, Hun-Jun Park, Yong Kyun Kim, Sun-Woong Kang
Organoids significantly advanced our comprehension of organ development, function, and disease modeling. This Perspective underscores the potential of heart-kidney-connected organoids in understanding the intricate relationship between these vital organs, notably the cardiorenal syndrome, where dysfunction in one organ can negatively impact the other. Conventional models fall short in replicating this complexity, necessitating an integrated approach. By co-culturing heart and kidney organoids, combined with microfluidic and 3D bioprinting technologies, a more accurate representation of in vivo conditions can be achieved...
March 2024: APL Bioengineering
https://read.qxmd.com/read/38416185/increased-cardiovascular-risk-in-patients-with-chronic-kidney-disease
#25
REVIEW
Sonja Vondenhoff, Stefan J Schunk, Heidi Noels
Cardiovascular disease (CVD) is highly prevalent in patients suffering from chronic kidney disease (CKD). The risk of patients with CKD developing CVD is manifested already in the early stages of CKD development. The impact of declined kidney function on increased cardiovascular risk and the underlying mechanisms are complex and multifactorial. This review discusses the impact of (a) traditional cardiovascular risk factors such as smoking, dyslipidemia, diabetes, and hypertension as well as (b) CKD-specific pathophysiological and molecular mechanisms associated with an increased cardiovascular risk...
February 28, 2024: Herz
https://read.qxmd.com/read/38387307/corrigendum-to-melatonin-fine-tunes-intracellular-calcium-signals-and-eliminates-myocardial-damage-through-the-ip3r-mcu-pathways-in-cardiorenal-syndrome-type-3-biochem-pharmacol-174-2020-113832
#26
Jin Wang, Sam Toan, Ruibing Li, Hao Zhou
No abstract text is available yet for this article.
February 21, 2024: Biochemical Pharmacology
https://read.qxmd.com/read/38385175/-in-chronic-kidney-disease-altered-cardiac-metabolism-precedes-cardiac-hypertrophy
#27
JOURNAL ARTICLE
Matthew J Williams, Carmen M Halabi, Hiral M Patel, Zachary Joseph, Kyle McCommis, Carla Weinheimer, Attila Kovacs, Florence Lima, Brian Finck, Hartmut Malluche, Keith A Hruska
Conduit arterial disease in CKD is an important cause of cardiac complications. Cardiac function in CKD has not been studied in the absence of arterial disease. In an Alport syndrome model bred not to have conduit arterial disease, mice at 225 days of life (dol) had CKD equivalent to human stage 4-5 CKD. PTH and FGF23 levels were one log order elevated, circulating sclerostin was elevated, and renal activin A was strongly induced. Aortic Ca levels were not increased and VSMC transdifferentiation was absent...
February 22, 2024: American Journal of Physiology. Renal Physiology
https://read.qxmd.com/read/38369134/mapk-nf-%C3%AE%C2%BAb-signaling-mediates-atrazine-induced-cardiorenal-syndrome-and-antagonism-of-lycopene
#28
JOURNAL ARTICLE
Fu-Wei Jiang, Jian-Ying Guo, Jia Lin, Shi-Yong Zhu, Xue-Yan Dai, Muhammad Asmat Ullah Saleem, Yi Zhao, Jin-Long Li
Atrazine (ATZ) is the most prevalent herbicide that has been widely used in agriculture to control broadleaf weeds and improve crop yield and quality. The heavy use of ATZ has caused serious environmental pollution and toxicity to human health. Lycopene (LYC), is a carotenoid that exhibits numerous health benefits, such as prevention of cardiovascular diseases and nephropathy. However, it remains unclear that whether ATZ causes cardiorenal injury or even cardiorenal syndrome (CRS) and the beneficial role of LYC on it...
February 16, 2024: Science of the Total Environment
https://read.qxmd.com/read/38342088/cell-specific-targeting-of-the-endothelium-in-the-cardiorenal-syndrome
#29
REVIEW
Nihay Laham-Karam, Johanna P Laakkonen, Seppo Yla-Herttuala, Annayya Aroor, Guanghong Jia, Adam Whaley-Connell
TThe vascular endothelium serves as a semi-selective permeable barrier as a conduit for transport of fluid, solutes and various cell populations between the vessel lumen and tissues. The endothelium thus has a dynamic role in the regulation of coagulation, immune system, lipid and electrolyte transport as well as neurohumoral influences on vascular tone and end-organ injury to tissues such as the heart and kidney. Within this framework, pharmacologic strategies for heart and kidney diseases including blood pressure, glycemic control and lipid reduction provide significant risk reduction yet certain populations are at risk for substantial residual risk for disease progression and treatment resistance and often have unwanted off-target effects leaving the need for adjunct, alternative targeted therapies...
February 9, 2024: Cardiorenal Medicine
https://read.qxmd.com/read/38322592/dual-specificity-phosphatase-1-interacts-with-prohibitin-2-to-improve-mitochondrial-quality-control-against-type-3-cardiorenal-syndrome
#30
JOURNAL ARTICLE
Nanyang Liu, Yanqiu Ding, Hao Zhou, Xing Chang, Long Lou
Type-3 cardiorenal syndrome (CRS-3) is acute kidney injury followed by cardiac injury/dysfunction. Mitochondrial injury may impair myocardial function during CRS-3. Since dual-specificity phosphatase 1 (DUSP1) and prohibitin 2 (PHB2) both promote cardiac mitochondrial quality control, we assessed whether these proteins were dysregulated during CRS-3-related cardiac depression. We found that DUSP1 was downregulated in heart tissues from a mouse model of CRS-3. DUSP1 transgenic (DUSP1 Tg ) mice were protected from CRS-3-induced myocardial damage, as evidenced by their improved heart function and myocardial structure...
2024: International Journal of Medical Sciences
https://read.qxmd.com/read/38312119/hepatocardiorenal-syndrome-in-liver-cirrhosis-recognition-of-a-new-entity
#31
REVIEW
Henry H L Wu, Amina Rakisheva, Arvind Ponnusamy, Rajkumar Chinnadurai
Emerging evidence and perspectives have pointed towards the heart playing an important role in hepatorenal syndrome (HRS), outside of conventional understanding that liver cirrhosis is traditionally considered the sole origin of a cascade of pathophysiological mechanisms directly affecting the kidneys in this context. In the absence of established heart disease, cirrhotic cardiomyopathy may occur more frequently in those with liver cirrhosis and kidney disease. It is a specific form of cardiac dysfunction characterized by blunted contractile responsiveness to stress stimuli and altered diastolic relaxation with electrophysiological abnormalities...
January 14, 2024: World Journal of Gastroenterology: WJG
https://read.qxmd.com/read/38305795/-cardiorenal-syndrome-in-geriatric-patients
#32
JOURNAL ARTICLE
Peter Dovjak
The unfavorable mutual influence of the kidney and heart functions in acute or chronic kidney and/or heart failure has defined the cardiorenal syndrome (CRS) since a consensus conference in 2004. The pathophysiological considerations and the subsequent treatment approaches determine the classification into five types. The syndrome has a high prevalence in geriatric patients. The interactions of medications on one or the other organ system require an interaction of treatment modalities in order to improve the prognosis and prevent acute deterioration...
February 2, 2024: Zeitschrift Für Gerontologie und Geriatrie
https://read.qxmd.com/read/38302775/renal-sympathetic-denervation-improves-pressure-natriuresis-relationship-in-cardiorenal-syndrome-insight-from-studies-with-ren-2-transgenic-hypertensive-rats-with-volume-overload-induced-using-aorto-caval-fistula
#33
JOURNAL ARTICLE
Zuzana Honetschlägerová, Zuzana Husková, Soňa Kikerlová, Janusz Sadowski, Elzbieta Kompanowska-Jezierska, Miloš Táborský, Zdenka Vaňourková, Petr Kujal, Luděk Červenka
The aim was to evaluate the effects of renal denervation (RDN) on autoregulation of renal hemodynamics and the pressure-natriuresis relationship in Ren-2 transgenic rats (TGR) with aorto-caval fistula (ACF)-induced heart failure (HF). RDN was performed one week after creation of ACF or sham-operation. Animals were prepared for evaluation of autoregulatory capacity of renal blood flow (RBF) and glomerular filtration rate (GFR), and of the pressure-natriuresis characteristics after stepwise changes in renal arterial pressure (RAP) induced by aortic clamping...
February 2, 2024: Hypertension Research: Official Journal of the Japanese Society of Hypertension
https://read.qxmd.com/read/38301611/practical-requirements-for-the-development-of-an-advanced-cardiorenal-unit
#34
REVIEW
Luis Almenar-Boneta, Ignacio Sánchez-Lázaro, Amparo Soldevila, Raquel López-Vilella, Víctor Donoso Trenado, Ramón Devesa, Paula Carmona, Sergi Tormo, María Jesús Montero Hernández, Julio Hernández, Luis Martínez Dolzb, Pilar Sánchez-Pérezd
BACKGROUND: Heart failure is frequently associated with kidney disease, and patients with kidney disease are at increased risk of heart failure. The co-occurrence of both entities not only significantly increases morbidity and mortality, but also complicates therapy. SUMMARY: Cardiorenal syndrome often requires a broad, comprehensive, and multidisciplinary approach. As a result, a need has arisen to create specialized cardiorenal units that allow for rigorous and personalized management of this condition...
February 1, 2024: Cardiorenal Medicine
https://read.qxmd.com/read/38285930/nitric-oxide-plays-a-dual-role-in-cardiorenal-syndrome-in-vitro-model
#35
JOURNAL ARTICLE
Giovana Marchini Armentano, Joana Claudio Pieretti, Carlos Alexandre Falconi, Amedea Barozzi Seabra, Marcela Sorelli Carneiro-Ramos
BACKGROUND/AIMS: Nitric oxide (NO) plays a dual role, acting as both an oxidant and a reducer, with various effects depending on its concentration and environment. Acute kidney injury's (AKI) pathogenesis observed in cardiorenal syndrome 3 (CRS 3) involves inflammatory responses and the production of reactive oxygen and nitrogen species. However, the role of NO on the development of CRS 3 is still not completely understood. The study aimed to mimic CRS 3 in vitro and investigate NO signaling and inflammatory molecules...
January 22, 2024: Cellular Physiology and Biochemistry
https://read.qxmd.com/read/38280805/natriuretic-peptide-testing-strategies-in-heart-failure-a-2023-update
#36
JOURNAL ARTICLE
Thanat Chaikijurajai, Hernan Rincon-Choles, W H Wilson Tang
Natriuretic peptides (NPs), including B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP), have been recommended as standard biomarkers for diagnosing heart failure (HF), and one of the strongest risk predictors for mortality and HF hospitalization regardless of ejection fraction (EF) and etiology of HF. BNP is an active neurohormone opposing renin-angiotensin-aldosterone and sympathetic nervous system overactivated in HF, whereas NT-proBNP is an inactive prohormone released from cardiomyocytes in response to wall stress...
2024: Advances in Clinical Chemistry
https://read.qxmd.com/read/38262118/effect-of-glucagon-like-peptide-1-receptor-agonists-and-sodium-glucose-cotransporter-2-inhibitors-on-time-to-outcome-in-type-2-diabetes-cardiorenal-outcome-trials
#37
JOURNAL ARTICLE
Alessandro Rizzi, David E Kloecker, Dario Pitocco, Kamlesh Khunti, Melanie J Davies, Francesco Zaccardi
INTRODUCTION: In randomized controlled trials (RCTs), treatment effects are commonly reported as hazard ratio, a measure often misinterpreted as a relative risk reduction. The acceleration factor (AF) indicates the extent to which a treatment increases/decreases the time before the occurrence of an outcome and gives useful insights in the interpretation of trials' results. METHODS: Using individual time-to-event data reconstructed from Kaplan-Meier plots, we estimated AFs for the primary outcomes (POs) and all-cause mortality in glucagon-like peptide-1 receptor agonists (GLP1-RAs) or sodium-glucose cotransporter-2 inhibitors (SGLT2-is) cardiorenal outcome trials in subjects with type 2 diabetes...
January 12, 2024: Diabetes & Metabolic Syndrome
https://read.qxmd.com/read/38255650/chronic-kidney-disease-associated-with-ischemic-heart-disease-to-what-extent-do-biomarkers-help
#38
REVIEW
Maria-Ruxandra Cepoi, Stefania Teodora Duca, Adriana Chetran, Alexandru Dan Costache, Marilena Renata Spiridon, Irina Afrăsânie, Sabina Andreea Leancă, Bianca-Ana Dmour, Iulian Theodor Matei, Radu Stefan Miftode, Larisa Miftode, Cristian Sorin Prepeliuc, Mihai Ștefan Cristian Haba, Minerva Codruța Bădescu, Irina Iuliana Costache
Chronic kidney disease represents a complex and multifaceted pathology characterized by the presence of structural or functional renal anomalies associated with a persistent reduction in renal function. As the disease progresses, complications arise due to the chronic inflammatory syndrome, hydro-electrolytic disorders, and toxicity secondary to the uremic environment. Cardiovascular complications are the leading cause of death for these patients. Ischemic cardiac pathology can be both a consequence and complication of chronic kidney disease, highlighting the need to identify specific cardiorenal dysfunction biomarkers targeting pathophysiological mechanisms common to both conditions...
December 25, 2023: Life
https://read.qxmd.com/read/38237563/clinical-significance-of-apela-in-acute-cardio-renal-insuffiency-of-chronic-heart-failure
#39
JOURNAL ARTICLE
Yani Zong, Yajie Wang, Yuexin Hu, Zhi Wang
INTRODUCTION: Apela has a wide range of biological effects on the cardiovascular system, but the changes and significance of endogenous Apela in patients with chronic heart failure (CHF) and acute deterioration of cardiac and renal function are unclear. METHODS: A total of 69 patients with stable CHF combined with well-preserved renal function were enrolled and followed for 12 months. The effects of Apela on human renal glomerular endothelial cells (hRGEC), human glomerular mesangial cells (hGMC) and human renal tubular epithelial cells (HK-2) were observed...
January 18, 2024: Kidney & Blood Pressure Research
https://read.qxmd.com/read/38236503/evaluation-of-renal-circulation-in-heart-failure-using-superb-microvascular-imaging-a-microvascular-flow-imaging-system
#40
JOURNAL ARTICLE
Shohei Kikuchi, Kiyomi Kayama, Yu Kawada, Shuichi Kitada, Yoshihiro Seo
PURPOSE: Renal circulation evaluation is essential in understanding the cardiorenal relationship in heart failure (HF), and there is a growing interest in imaging techniques that visualize renal circulation. This study aimed to assess the effectiveness of superb microvascular imaging (SMI) in evaluating renal circulation in HF patients. METHOD: The study included 71 HF patients undergoing cardiac catheterization. Prior to catheterization, renal ultrasound examinations were performed...
January 18, 2024: Journal of Medical Ultrasonics
keyword
keyword
12232
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.